German Cancer Consortium (DKTK)
The German Cancer Consortium (“Deutsches Konsortium für Translationale Krebsforschung”, DKTK) is a joint, long-term initiative of the Federal Ministry of Research, Technology and Space (BMFTR), the participating federal states and the German Cancer Research Center (DKFZ) as the core center.
Who we are
In 2012, the German Cancer Consortium (“Deutsches Konsortium für Translationale Krebsforschung”, DKTK), was founded as one of the German Centers for Health Research (“Deutsche Zentren der Gesundheitsforschung”, DZG). The mission of DKTK is to make advances in prevention, diagnostics, early detection and therapy of cancer usable for patients more quickly through translational research. Scientists in the DKTK primarily work on preclinical translational research topics – meaning at the interface between basic and clinical research. It also supports reverse translation in order to follow-up on study results that require further scientific elucidation.
DKTK is a joint long-term initiative of the Federal Ministry of Research, Technology and Space (BMFTR), the participating federal states and the German Cancer Research Center (DKFZ). In its role as DKTK’s core center, the DKFZ joins forces with more than 20 research institutions and university clinics with particular oncological expertise in translation centers at eight partner sites in Germany: Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich and Tübingen.